Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes

NCT00974090 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

194

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)
DRUG: Teneli / Teneli + SU

Sponsor

Tanabe Pharma Corporation